Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 308 participants.

Also called NCT02683746

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 308 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02683746
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02683746. Randomized; double masking; primary purpose treatment. Start 2016-03-16 (actual); primary completion 2017-04-03 (actual). Results posted on 2018-05-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Lyophilized albiglutide DCC pen injector
Intervention (Drug)
Lyophilized albiglutide DCC pen injector matching placebo
Intervention (Drug)
Albiglutide liquid auto-injector
Intervention (Drug)
Albiglutide liquid auto-injector matching placebo
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct02683746
Content hash
4c97823d524bb307fdc1a3ed77a912400a4acd2a7f50b73c70be9f7c2616fe0a